New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure

No abstract is available for this paper.

• Publication year

  2019

• Venue

  JN. Journal of Nephrology (Milano. 1992)

• Publication date

  2019-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40620-019-00600-7PMID 30989614
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice

  2018cited by this paper
• The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.

  2018cited by this paper
• New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention.

  2018cited by this paper
• Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney Disease: Role of Oxidative Stress

  2017cited by this paper
• 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

  2017cited by this paper
• Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1.

  2017cited by this paper
• Aldosterone-induced expression of ENaC-α is associated with activity of p65/p50 in renal epithelial cells

  2017cited by this paper
• Aldosterone Target NGAL (Neutrophil Gelatinase–Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NF&kgr;B Pathway

  2017cited by this paper
• Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis

  2017cited by this paper
• Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys

  2017cited by this paper
• Renin-angiotensin system blockade: Finerenone.

  2017cited by this paper
• Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology

  2017cited by this paper
• The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury

  2017cited by this paper
• Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence

  2017cited by this paper
• Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload–Induced Cardiac Injury

  2016cited by this paper
• Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy

  2016cited by this paper
• Genomic and rapid effects of aldosterone: what we know and do not know thus far

  2016influential reference
• A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

  2016cited by this paper
• Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena.

  2016cited by this paper
• Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety

  2016cited by this paper
• Cardiac Tissue Injury and Remodeling Is Dependent Upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages.

  2016cited by this paper
• Low glomerular filtration rate and risk of myocardial infarction: A systematic review and meta-analysis.

  2016cited by this paper
• CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats

  2016cited by this paper
• Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1*

  2015cited by this paper
• CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.

  2015cited by this paper
• Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

  2015cited by this paper
• Relation of aortic valve calcium to chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study).

  2015cited by this paper
• Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.

  2015cited by this paper
• Underprescription of Renin–Angiotensin System Blockers in Moderate to Severe Chronic Kidney Disease

  2015cited by this paper
• Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology

  2015cited by this paper
• Intersection of cardiovascular disease and kidney disease: atrial fibrillation

  2014cited by this paper
• Emerging drugs for chronic kidney disease

  2014cited by this paper
• Aldosterone synthase inhibitors in cardiovascular and renal diseases.

  2014cited by this paper
• Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

  2014cited by this paper
• Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.

  2014cited by this paper
• Incidence and Predictors of Postoperative Atrial Fibrillation in Kidney Transplant Recipients

  2013cited by this paper
• Aldosterone and cardiovascular disease: the heart of the matter.

  2013cited by this paper
• Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms.

  2012cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  2012cited by this paper
• Oxidative Stress Causes Mineralocorticoid Receptor Activation in Rat Cardiomyocytes: Role of Small GTPase Rac1

  2012cited by this paper
• Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study.

  2011cited by this paper
• Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction

  2011cited by this paper
• Minireview: Aldosterone and mineralocorticoid receptors: past, present, and future.

  2010cited by this paper
• Aldosterone and mineralocorticoid receptors in the cardiovascular system.

  2010cited by this paper
• Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

  2009cited by this paper
• Corticosteroid receptors, macrophages and cardiovascular disease.

  2009cited by this paper
• Use of aldosterone antagonists in heart failure.

  2009cited by this paper
• Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.

  2008cited by this paper
• Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.

  2005cited by this paper
• Mineralocorticoid-receptor blockade, hypertension and heart failure

  2005cited by this paper
• Mineralocorticoid Receptors: Distribution and Activation

  2005cited by this paper
• Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status.

  2004cited by this paper
• Rapid effects of aldosterone on vascular cells: clinical implications.

  2004cited by this paper
• Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

  2002cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction.

  1986cited by this paper
• Plasma aldosterone concentrations in chronic renal disease.

  1982cited by this paper
• Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure.

  1978cited by this paper

• Mineralocorticoid receptor antagonists in internal medicine practice

  2026cites this paper
• The Mechanism of Action of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction

  2026cites this paper
• Machine learning-based prediction model for 30-day readmission risk in elderly patients with type 2 diabetes mellitus and heart failure: a retrospective cohort study with SHAP interpretability analysis

  2026cites this paper
• Renal-Cardiac Crosstalk in the Pathogenesis and Progression of Heart Failure

  2025cites this paper
• Individualized Diets in Patients with Kidney Disease and Kidney Transplants: A Narrative Review

  2025cites this paper
• Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases

  2025cites this paper
• Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.

  2025cites this paper
• Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials

  2024cites this paper
• Finerenone as a Novel Treatment for Gitelman Syndrome: A Case Study of a 35-Year-Old Male with Adrenal Mass and Hypokalemia

  2024cites this paper
• Clinical Management of Primary Aldosteronism: An Update

  2024cites this paper
• Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease

  2024cites this paper
• T cell Mineralocorticoid Receptor Deficiency Attenuates Pathological Ventricular Remodeling After Myocardial Infarction.

  2023cites this paper
• Bioinspired optical and electrical dual-responsive heart-on-a-chip for hormone testing.

  2023cites this paper
• Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients

  2023cites this paper
• Gene expression analysis to identify mechanisms underlying improvement of myocardial fibrosis by finerenone in SHR.

  2023cites this paper
• New possibilities of nephroprotection in type 2 diabetes using finerenone Consensus of the board of experts

  2023cites this paper
• Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists

  2023cites this paper
• Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteers.

  2023cites this paper
• Post-COVID-19 syndrome increased the requirement for corticosteroids in a dialysis patient with preexisting adrenal insufficiency

  2023cites this paper
• Impaired negative feedback and death following acute stress in glucocorticoid receptor knockout Xenopus tropicalis tadpoles.

  2022cites this paper
• Hypertension in chronic kidney disease: What lies behind the scene

  2022cites this paper
• Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction.

  2022cites this paper
• Pathophysiology of bilateral hyperaldosteronism

  2022cites this paper
• Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.

  2022cites this paper
• Promising directions in the treatment of chronic heart failure: improving old or developing new ones?

  2022cites this paper
• Effects of sodium‐glucose cotransporter‐2 inhibitors and aldosterone antagonists, in addition to renin‐angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta‐analysis

  2022influential citation
• Effective Perturbations by Small-Molecule Modulators on Voltage-Dependent Hysteresis of Transmembrane Ionic Currents

  2022cites this paper
• Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure

  2022cites this paper
• Zinc oxide nanoparticles and spironolactone-enhanced Nrf2/HO-1 pathway and inhibited Wnt/β-catenin pathway in adenine-induced nephrotoxicity in rats

  2022cites this paper
• The Road to Better Management in Resistant Hypertension—Diagnostic and Therapeutic Insights

  2021cites this paper
• Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans

  2021cites this paper
• Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease

  2021cites this paper
• Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care

  2021cites this paper
• ADEQUATE BLOOD PRESSURE CONTROL UNATTAINABLE WITHOUT ADEQUATE RECOGNITION AND TREATMENT OF PRIMARY ALDOSTERONISM.

  2021cites this paper
• Tailoring the management of hypertension to comorbidities

  2021cites this paper
• DNA Methylation of the Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene, CYP11B2 in Cardiovascular Diseases

  2021cites this paper
• Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease

  2021cites this paper
• Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker

  2021cites this paper
• Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease

  2021cites this paper
• Vascular cell-specific roles of mineralocorticoid receptors in pulmonary hypertension

  2021cites this paper
• Finerenone: First Approval

  2021cites this paper
• Advances in Clinical Research in Chronic Kidney Disease

  2021influential citation
• Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease

  2021cites this paper
• Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics

  2021cites this paper
• Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria

  2021cites this paper
• The mineralocorticoid receptor in chronic kidney disease

  2021cites this paper
• Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension

  2021cites this paper
• Diuretics in chronic kidney disease

  2020cites this paper
• The expanding class of mineralocorticoid receptor modulators: New ligands for kidney, cardiac, vascular, systemic and behavioral selective actions.

  2020influential citation
• Диуретики при хронической болезни почек

  2020cites this paper
• A retrospective cohort study of clinical characteristics, treatment patterns, and disease outcomes of chronic kidney disease in patients with diabetes using a Japanese claims database

  2020cites this paper
• Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results

  2020cites this paper
• Effects of MIneralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio (ARR) In Primary Aldosteronism-EMIRA Study.

  2020cites this paper
• Aldosteronismo primário. Revisão do estado da arte do JACC

  2020cites this paper
• Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis.

  2020cites this paper
• Drug-Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone with Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers.

  2020cites this paper
• Finerenone - Halting Relative Hyperaldosteronism in Chronic Kidney Disease.

  2020cites this paper
• Mineralocorticoid receptor antagonists in patients with chronic kidney disease.

  2020cites this paper
• Primary aldosteronism in elderly, old, and very old patients

  2020cites this paper
• Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers

  2020cites this paper
• Primary Aldosteronism

  2020cites this paper
• Pathogenesis and treatment of primary aldosteronism

  2020cites this paper
• Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?

  2020cites this paper
• The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism

  2020cites this paper
• Pharmacokinetics of Diuretics , Resistance to Diuretic Treatment in Patients with Chronic Kidney Disease

  2020cites this paper
• Proteolytic Activation of the Epithelial Sodium Channel in Nephrotic Syndrome by Proteasuria: Concept and Therapeutic Potential

  2020cites this paper
• Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence.

  2019cites this paper
• Primary Aldosteronism: JACC State-of-the-Art Review.

  2019cites this paper
• An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?

  2019influential citation
• Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how?

  2019cites this paper